Association of immune evasion in myeloid sarcomas with disease manifestation and patients' survival.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 05 03 2024
accepted: 22 07 2024
medline: 22 8 2024
pubmed: 22 8 2024
entrez: 22 8 2024
Statut: epublish

Résumé

Myeloid sarcomas (MS) comprise rare extramedullary manifestations of myeloid neoplasms with poor patients' outcome. While the clinical relevance of the tumor microenvironment (TME) is well established in many malignancies, there exists limited information in MS. The expression of the human leukocyte antigen class I (HLA-I) antigens, HLA-I antigen processing and presenting machinery (APM) components and the composition of the TME of 45 MS and paired bone marrow (BM) samples from two independent cohorts were assessed by immunohistochemistry, multispectral imaging, and RNA sequencing (RNAseq). A significant downregulation of the HLA-I heavy chain (HC; 67.5%) and ß2-microglobulin (ß2M; 64.8%), but an upregulation of HLA-G was found in MS compared to BM samples, which was confirmed in a publicly available dataset. Moreover, MS tumors showed a predominantly immune cell excluded TME with decreased numbers of tissue infiltrating lymphocytes (TILs) (9.5%) compared to paired BM (22.9%). RNAseq analysis of a subset of 10 MS patients with preserved and reduced HLA-I HC expression revealed 150 differentially expressed genes and a significantly reduced expression of inflammatory response genes was found in samples with preserved HLA-I expression. Furthermore, low HLA-I expression and low TIL numbers in the TME of MS cases were linked to an inferior patients' outcome. This study demonstrated a high prevalence of immune escape strategies in the pathogenesis and extramedullary spread of MS, which was also found in patients without evidence of any BM pathology, which yields the rational for the development of novel individually tailored therapies for MS patients.

Identifiants

pubmed: 39170623
doi: 10.3389/fimmu.2024.1396187
pmc: PMC11336574
doi:

Substances chimiques

Histocompatibility Antigens Class I 0
beta 2-Microglobulin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1396187

Informations de copyright

Copyright © 2024 Bauer, Monecke, Hackl, Wilfer, Jaekel, Bläker, Al-Ali, Seliger and Wickenhauser.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Marcus Bauer (M)

Institute of Pathology, Martin Luther University Halle-Wittenberg, Halle, Germany.

Astrid Monecke (A)

Institute of Pathology, University Leipzig, Leipzig, Germany.

Hubert Hackl (H)

Institute of Bioinformatics, Biocenter, Medical University Innsbruck, Innsbruck, Austria.

Andreas Wilfer (A)

Institute of Pathology, Martin Luther University Halle-Wittenberg, Halle, Germany.
Krukenberg Cancer Center Halle, University Hospital Halle, Martin Luther University Halle-Wittenberg, Halle, Germany.

Nadja Jaekel (N)

Department of Hematology, University Hospital Halle, Martin Luther University Halle-Wittenberg, Halle, Germany.

Hendrik Bläker (H)

Institute of Pathology, University Leipzig, Leipzig, Germany.

Haifa Kathrin Al-Ali (HK)

Krukenberg Cancer Center Halle, University Hospital Halle, Martin Luther University Halle-Wittenberg, Halle, Germany.
Department of Hematology, University Hospital Halle, Martin Luther University Halle-Wittenberg, Halle, Germany.

Barbara Seliger (B)

Medical Faculty, Martin Luther University Halle-Wittenberg, Halle, Germany.
Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.
Institute of Translational Immunology, Medical School "Theodor Fontane", Brandenburg an der Havel, Germany.

Claudia Wickenhauser (C)

Institute of Pathology, Martin Luther University Halle-Wittenberg, Halle, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH